Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.

Portal hypertension & cirrhosis Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI:10.1002/poh2.70033

Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G Duda, Ao Huang, Jian Zhou

{"title":"Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.","authors":"Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G Duda, Ao Huang, Jian Zhou","doi":"10.1002/poh2.70033","DOIUrl":null,"url":null,"abstract":"<p><p>Primary liver cancer remains a significant global public health challenge, characterized by persistently high incidence and mortality. This review synthesizes current epidemiological data to analyze trends and etiological shifts, with particular emphasis on China, which bears over 40% of the global burden. Findings highlight a transition in dominant risk factors from viral hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD), alongside persistent threats from aflatoxin exposure and lifestyle behaviors. Evidence-based prevention strategies, including universal hepatitis B virus (HBV) vaccination, antiviral therapy expansion, aflatoxin control, and early metabolic intervention, are critical to reducing disease burden. The integration of artificial intelligence into screening and management represents a promising advancement. A multi-faceted approach combining vaccination, surveillance, lifestyle modification, and technological innovation is essential for effective global liver cancer control.</p>","PeriodicalId":520976,"journal":{"name":"Portal hypertension & cirrhosis","volume":"5 1","pages":"65-95"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13367031/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Portal hypertension & cirrhosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/poh2.70033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Primary liver cancer remains a significant global public health challenge, characterized by persistently high incidence and mortality. This review synthesizes current epidemiological data to analyze trends and etiological shifts, with particular emphasis on China, which bears over 40% of the global burden. Findings highlight a transition in dominant risk factors from viral hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD), alongside persistent threats from aflatoxin exposure and lifestyle behaviors. Evidence-based prevention strategies, including universal hepatitis B virus (HBV) vaccination, antiviral therapy expansion, aflatoxin control, and early metabolic intervention, are critical to reducing disease burden. The integration of artificial intelligence into screening and management represents a promising advancement. A multi-faceted approach combining vaccination, surveillance, lifestyle modification, and technological innovation is essential for effective global liver cancer control.

查看原文本刊更多论文

全球和中国原发性肝癌趋势：GLOBOCAN 2022数据分析和疾病管理意义

原发性肝癌仍然是一个重大的全球公共卫生挑战，其特点是发病率和死亡率一直很高。本综述综合了目前的流行病学数据，以分析趋势和病因学变化，并特别强调了承担全球负担40%以上的中国。研究结果强调了主要危险因素从病毒性肝炎到代谢功能障碍相关脂肪变性肝病（MASLD）的转变，以及黄曲霉毒素暴露和生活方式行为的持续威胁。以证据为基础的预防策略，包括普及乙型肝炎病毒（HBV）疫苗接种、扩大抗病毒治疗、黄曲霉毒素控制和早期代谢干预，对减轻疾病负担至关重要。将人工智能整合到筛查和管理中是一个很有前途的进步。结合疫苗接种、监测、生活方式改变和技术创新的多方面方法对于有效的全球肝癌控制至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Portal hypertension & cirrhosis

自引率

0.00%

发文量